Safety and immunological effectiveness of the domestic combined trivaccine for the prevention of measles, rubella and mumps Vaktrivir^® in children 12 months and 6 years of age (results of a simple blind multicenter comparative randomized clinical trial)

Relevanc. Measles, mumps and rubella, despite many years of vaccination, retain their epidemiological and social significance at the present time.

The aim of the work is to study the safety and immunogenicity. Of the vaccine for the prevention of measles, rubella and mumps Vactrivir® in children's immunization.

Materials and methods. The safety and immunogenicity of the vaccine was studied in a simple multicenter blind comparative randomized clinical trial involving children aged 12 months and 6 years.

Results. The Vactrivir® vaccine is characterized by low reactogenicity, a high safety and immunogenicity profile and is comparable in terms of indicators to the foreign Priorix® vaccine, which has been used in the Russian Federation for specific prevention of measles, rubella and mumps since 2018.

1. https://www.who.int/immunization/newsroom/measles-data-2019/ru/

2. https://www.who.int/csr/don/26-november-2019-measles-global_situation/ru/

3. Yuminova N. V., et al. Risks of delay in the implementation of the international program for the elimination of measles and reducing the incidence of mumps in the Russian Federation of the who European region. Prospects for the introduction of innovative technologies in medicine and pharmacy. 2019:248–251.

4. Tolokonnikova H. P., Litvina L. A. Significance of measles for the modern world //Problems of biology, animal science and biotechnology. – 2019. – P. 183–187.

5. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2019: State report. M.: Federal service for supervision of consumer rights protection and human welfare, 2020. – 299 p.

6. Yunasova T. N., et al. Analysis of the incidence of measles in Russia and the problems of measles prevention at the elimination stage. Prevention, diagnosis, and treatment. – 2019. – Vol. 19. – №. 3.

7. Tsvirkun O. V.. et al. Characteristics of population immunity to measles in the Russian Federation. Epidemiology and Vaccinal Prevention. 2020;19(4):6–13.

8. Strategy for the development of immunoprophylaxis of infectious diseases for the period up to 2035, decree of the Government of the Russian Federation No. 2390-R of September 18, 2020

9. Immunoprophylaxis-2018. Handbook, 13th edition, expanded.

10. Turaeva N. V., et al. Elimination of rubella infection in Russia //Scientific support of anti-epidemic protection of the population: current problems and solutions. – 2019. – Pp. 115–117.

11. Hashimoto H., et all. Pediatr. Infect. Dis. J.2009;28(3):173–175.

12. https://www.who.int/ru/news-room/fact-sheets/detail/rubella

13. kolyshkin V. M., Sidorenko E. S., Sukhanova L. L. Combined vaccine for immunoprophylaxis of measles, mumps and rubella. – 2018.

14. Gaiderova L. A., et al. Post-registration evaluation of the Indian combined measles, mumps and rubella vaccine. Epidemiology and Vaccinal Prevention. 2005;6:22–24.

15. Tatochenko V. K. New trivaccine against measles, rubella and mumps Priorix®. Questions of modern Pediatrics. – 2002. – Vol. 1. – No. 2. – P. 1–4;

16. Menshikova M. G., et al. Assessment of the safety and immunogenicity of a new domestic combined vaccine for the prevention of measles, rubella and mumps //Prospects for the development of production and use of immunobiological drugs in the XXI century. – 2018. – P. 90–94.

17. Trukhacheva, N. V. Mathematical statistics in medical and biological research using the STATISTICA package – M.: GEOTAR-Media, 2013. – 379 p.